Mediators of Inflammation

Mediators of Inflammation / 1999 / Article

Open Access

Volume 8 |Article ID 129859 | https://doi.org/10.1080/09629359990496

A. L. Pukhalsky, N. I. Kapranov, E. A. Kalashnikova, G. V. Shmarina, L. A. Shabalova, S. N. Kokarovtseva, D. A. Pukhalskaya, N. J. Kashirskaja, O. I. Simonova, "Inflammatory Markers in Cystic Fibrosis Patients with Lung Pseudomonas Aeruginosa Infection", Mediators of Inflammation, vol. 8, Article ID 129859, 9 pages, 1999. https://doi.org/10.1080/09629359990496

Inflammatory Markers in Cystic Fibrosis Patients with Lung Pseudomonas Aeruginosa Infection

Abstract

Chronic endobronchial inflammation and bacterial infection are the main causes of morbidity and mortality in cystic fibrosis (CF), an autosomal recessive genetic disorder associated with improper function of chloride channels. Inflammation in CF lung is greatly amplified after Pseudomonas aeruginosa infection. In this study the relationship between P. aeruginosa status and inflammatory markers has been investigated. Seventeen CF children in acute lung exacerbation were examined. CF patients without P. aeruginosa infection were characterized by elevated activity of sputum elastase, reduced response of peripheral blood lymphocytes to PHA and significant resistance to the antiproliferative action of glucocorticoids. These parameters were normalized after antibiotic treatment. The patients with prolonged P. aeruginosa infection demonstrated extremely high levels of elastase activity and elevated amounts of sputum IL-8 and TNF-α. Although antibiotic treatment resulted in clinical improvement, it failed to suppress excessive immune response in the lung. The data indicate that CF patients with prolonged P. aeruginosa need the modified treatment, which should include immunomodulating drugs and protease inhibitors as well as antibacterial therapy.

Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views165
Downloads471
Citations

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.